Amgen walks away from PBAC – again
By Megan Brodie 1 year ago | In Companies, Products, Reimbursement- 1 year ago
4 July 2025 Amgen has withdrawn its promising first-in-class bispecific T-cell engager (BiTE) therapy IMDELLTRA…
This is subscriber-only content. Please login to continue reading.